FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
Ιř									
I	OMB Number:	3235-0287							
I	Estimated average burden								
I	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Santillana Sergio L.			<u>N</u>	2. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [MACK]					NC Ch	5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Ow Officer (give title Other (st			ner		
(Last) (First) (Middle) C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201					3. Date of Earliest Transaction (Month/Day/Year) 06/13/2017						X Officer (give title Other (specify below) Chief Medical Officer				
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		Code (Instr.		ed (A) or tr. 3, 4 and	5. Amoun Securities Beneficia Owned Fo Reported	s Fo lly (D ollowing (I)	orm: Direct) or Indirect (Instr. 4)	7. Nature of ndirect Beneficial Dwnership Instr. 4)			
							Code V	Amount	(A) o	Price	Transacti (Instr. 3 a	on(s)		,iiisti. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date Execution Date, if any (Month/Day/Year)		Code (ransaction Derivative ode (Instr. Securities		re s I (A) sed str.	Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	<i>3</i>)	
Stock Option (right to buy)	\$1.35	06/13/2017		A		450,000		(1)	06/12/2027	Common Stock	450,000	\$0.00	450,000	D	

Explanation of Responses:

1. This option vests as to 1/6th of the total number of shares granted on 12/12/17 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until

Remarks:

/s/ Brian J. Kickham, attorney-

06/15/2017

in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.